Table 1.

Artemisinin and partner drug studies used to inform the resistance scenarios

Location	Pailin, Cambodia	Pursat, Cambodia	Oddar Meanchey Province, Cambodia	Tasanh, Cambodia	Sudan and Uganda
Reference	Leang et al. [16]	Leang et al. [16]	Spring et al. [17]	Bethell et al. [18]	Mukhtar et al. [19]a; Priotto et al. [20]b
Drugs given	DHA-PQP	DHA-PQP	DHA-PQP	AS	AS + SP
Percentage of treated individuals with slow parasite clearance	32.2 %	8.6 %	54 %	48.2 %	3.5b %
Slow parasite clearance time (days)	8.91c	6.04c	10.26	10.86c	5.42c
Percentage of treated individuals that recrudesce to LCF	2.7 %	5.4 %	21 %	1.6d %	3.9a %
Percentage of individuals that recrudesce to LPF	10.7 %	0 %	24 %	4.8d %	10.4a %
Time to recrudesce (days)	26.9	25.6	27.1	24.5e	25.3a
Summary	Medium artemisinin and partner drug resistance	Low artemisinin and partner drug resistance	High artemisinin and partner drug resistance	High artemisinin resistance	No artemisinin resistance and high partner drug resistance

^a,bDenotes which study each value was obtained (a = Mukhtar et al. [19], b = Priotto et al. [20])

^cThese values were not given in the studies and were derived from data—see Additional file 1: Supplementary methods for details

^dValues not given in paper, only total proportion of people recrudescing (6.4 %)—this was split up to match the LCF:LPF ratio from the 2010 Tasanh study

^eNot given in paper, assumed to be same as 2010 Tasanh study